Biohit Oyj B-shares subscribed with Stock Options I 2013 B
NOTICE OF BIOHIT OYJ’S ANNUAL GENERAL MEETING
Publication of Biohit Oyj Annual Report 2016
Vitafoods Europe 2017
Biohit Oyj is a globally operating Finnish biotechnology company. We produce innovative products and services to promote research and early diagnosis.
Biohit's operations are based on a goal-oriented and long-term innovation and patenting strategy. Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract.
The key objective of the diagnostics business is to prevent diseases of the gastrointestinal tract. Biohit HealthCare has products and analysis systems for the early diagnosis of gastrointestinal diseases, such as the blood-sample based GastroPanel® examinations for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, and the ColonView examination for the early detection of fecal occult intestinal bleeding (faecal occult blood) that indicates a risk of colorectal cancer. The Acetium innovation was developed to reduce carcinogenic acetaldehyde in the gastrointestinal tract.
Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. The Biohit Group employs around 50 people. Biohit's series B share (BIOBV) is quoted on NASDAQ OMX Helsinki, Small cap/Healthcare since 1999. Biohit's products are sold by many distributors around the world. More information about the share and financials is available in the Investors section of this site.